India Pharma Outlook Team | Thursday, 25 September 2025
AbbVie, a global biopharmaceutical leader, hosted the National Conclave on World Retina Day at the India Habitat Centre, Delhi, which focused on Diabetic Macular Edema (DME) being the leading cause of vision loss among people living with diabetes.
The Managing Director & General Manager, AbbVie India, Suresh Pattathil, said, AbbVie, with over 75 years of global eyecare experience, is committed to improving the lives of 3 million DME patients in India. Early detection, access to innovative therapies, and awareness are crucial steps in both the prevention of vision loss and the ensuring of a quality life.
The panel has suggested that routine retinal screening should be integrated with diabetes care so as to give access to therapies to a larger number of people and also to make use of technology for early diagnosis especially in rural and semi-urban areas.
The experts have shared the available treatment options which include anti-VEGF short-acting injections, long-acting corticosteroid implants, and laser therapies while at the same time, patient education and drop-in care are highlighted as two of the most vital aspects.
Also Read: Sanofi Ventures Secures $625M to Strengthen Biotech Innovation
DME is the condition when the retinal blood vessels are damaged by continuous high blood sugar which will cause the fluid to collect in the macula resulting in the area getting swollen and the central vision being lost.
AbbVie is showing its commitment to the cause of avoidable vision loss through its education, innovation, and partnership programs in different parts of the country as evidenced by this conclave.
